Mainstream

Insmed outlines $405M–$425M ARIKAYCE revenue target as brensocatib nears launch and pipeline advances

Insmed outlines $405M–$425M ARIKAYCE revenue target as brensocatib nears launch and pipeline advances

Post ContentinsmRead More

You might also be interested in reading Huobi Exchange to Empower Women in Crypto, Says Justin Sun.

August 8, 2025
In Mainstream